메뉴 건너뛰기




Volumn 17, Issue 7, 2007, Pages

Treatment of HIV-associated dyslipidemia: A role for omega-3 fatty acids

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ANTITHROMBOCYTIC AGENT; BEZAFIBRATE; CLOPIDOGREL; COUMARIN DERIVATIVE; DOCOSAHEXAENOIC ACID; EFAVIRENZ; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INDINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TRIACYLGLYCEROL; UNINDEXED DRUG;

EID: 34547687746     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (11)

References (88)
  • 1
    • 0042832397 scopus 로고    scopus 로고
    • Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Diseases Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
    • Dube M, Stein J, Aberg J, et al; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Diseases Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
    • (2003) Clin Infect Dis , vol.37 , pp. 613-627
    • Dube, M.1    Stein, J.2    Aberg, J.3
  • 3
    • 27944508736 scopus 로고    scopus 로고
    • High-risk dysmetabolism disorders associated with HAART treated HIV disease and reimbursement of lipid lowering drugs, in a clinical and a socio-economic perspective
    • Manfredi R. High-risk dysmetabolism disorders associated with HAART treated HIV disease and reimbursement of lipid lowering drugs, in a clinical and a socio-economic perspective. AIDS Rev. 2005; 7:155-160.
    • (2005) AIDS Rev , vol.7 , pp. 155-160
    • Manfredi, R.1
  • 4
    • 0038065609 scopus 로고    scopus 로고
    • Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: An index of atherogenicity?
    • Badiou S, Merle De Boever C, Dupuy AM, et al. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis. 2003;168:107-113.
    • (2003) Atherosclerosis , vol.168 , pp. 107-113
    • Badiou, S.1    Merle De Boever, C.2    Dupuy, A.M.3
  • 5
    • 0037126526 scopus 로고    scopus 로고
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • National Cholesterol Education Program NCEP
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106:3143-3421.
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 6
    • 27744566719 scopus 로고    scopus 로고
    • Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: An 8-week, randomized, double-blind, placebo-controlled study
    • Davidson MH, Bays H, Rhyne J, et al. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Clin Tner. 2005;27:715-727.
    • (2005) Clin Tner , vol.27 , pp. 715-727
    • Davidson, M.H.1    Bays, H.2    Rhyne, J.3
  • 7
    • 33845625228 scopus 로고    scopus 로고
    • Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Studv A5148 Study Team
    • Dube MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Studv A5148 Study Team. Antivir Ther. 2006;11:1081-1089.
    • (2006) Antivir Ther , vol.11 , pp. 1081-1089
    • Dube, M.P.1    Wu, J.W.2    Aberg, J.A.3
  • 8
    • 33847330109 scopus 로고    scopus 로고
    • Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: A randomized prospective study
    • De Truchis P, Kirstetter M, Perier A, et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr. 2007;44:278-285.
    • (2007) J Acquir Immune Defic Syndr , vol.44 , pp. 278-285
    • De Truchis, P.1    Kirstetter, M.2    Perier, A.3
  • 9
    • 27644547395 scopus 로고    scopus 로고
    • Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia
    • Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005;41:1498-1504.
    • (2005) Clin Infect Dis , vol.41 , pp. 1498-1504
    • Wohl, D.A.1    Tien, H.C.2    Busby, M.3
  • 10
    • 64149092750 scopus 로고    scopus 로고
    • Effect of a low dose of salmon oil on triglycerides and lipid parameters in HIV patients receiving a HAART regimen and having elevated serum triglyceride levels and total cholesterol/high density lipoprotein ratio
    • February 5-8, Denver. Abstract 756
    • Baril JG, Kovacs C, Trottier S, et al. Effect of a low dose of salmon oil on triglycerides and lipid parameters in HIV patients receiving a HAART regimen and having elevated serum triglyceride levels and total cholesterol/high density lipoprotein ratio. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver. Abstract 756.
    • (2006) 13th Conference on Retroviruses and Opportunistic Infections
    • Baril, J.G.1    Kovacs, C.2    Trottier, S.3
  • 11
    • 0042262057 scopus 로고    scopus 로고
    • Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome
    • Grunfeld C, Tien R Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis. 2003;37(suppl 2): S43-S46.
    • (2003) Clin Infect Dis , vol.37 , Issue.SUPPL. 2
    • Grunfeld, C.1    Tien, R.2
  • 12
    • 0025872834 scopus 로고
    • Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
    • Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90:154-162.
    • (1991) Am J Med , vol.90 , pp. 154-162
    • Grunfeld, C.1    Kotler, D.P.2    Shigenaga, J.K.3
  • 13
    • 0037000618 scopus 로고    scopus 로고
    • Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome
    • Christeff N, Melchior JC, De Truchis P, et al. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest. 2002;32: 43-50.
    • (2002) Eur J Clin Invest , vol.32 , pp. 43-50
    • Christeff, N.1    Melchior, J.C.2    De Truchis, P.3
  • 14
    • 0033583977 scopus 로고    scopus 로고
    • Diagnosis, prediction, and natural course of HIV-1 pro tease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus
    • Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 pro tease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus. Lancet. 1999;353:2093-2099.
    • (1999) Lancet , vol.353 , pp. 2093-2099
    • Carr, A.1    Samaras, K.2    Thorisdottir, A.3
  • 15
    • 0033040212 scopus 로고    scopus 로고
    • Hyperlipidemia under treatment with proteiase inhibitors
    • Segerer S, Bogner JR, Walli R, et al. Hyperlipidemia under treatment with proteiase inhibitors. Infection. 1999;27:77-81.
    • (1999) Infection , vol.27 , pp. 77-81
    • Segerer, S.1    Bogner, J.R.2    Walli, R.3
  • 16
    • 0242636456 scopus 로고    scopus 로고
    • Endothelial function in HIV-infected patients receiving protease inhibitor therapy: Does immune competence affect cardiovascular risk?
    • Nolan D, Watts GF, Herrmann SE, et al. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? Q J Med. 2003;96:825-832.
    • (2003) Q J Med , vol.96 , pp. 825-832
    • Nolan, D.1    Watts, G.F.2    Herrmann, S.E.3
  • 17
    • 27744590942 scopus 로고    scopus 로고
    • Indinavir impairs endothelial function in healthy HIV-negative men
    • Shankar SS, Dube MP, Gorski JC, et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005;150:933.
    • (2005) Am Heart J , vol.150 , pp. 933
    • Shankar, S.S.1    Dube, M.P.2    Gorski, J.C.3
  • 19
    • 25144511573 scopus 로고    scopus 로고
    • Mechanisms of lipid elevations associated with the treatment of patients with HIV infection
    • Piliero PJ. Mechanisms of lipid elevations associated with the treatment of patients with HIV infection. MedGenMed. 2003;5:1.
    • (2003) MedGenMed , vol.5 , pp. 1
    • Piliero, P.J.1
  • 20
    • 19644395095 scopus 로고    scopus 로고
    • Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India
    • Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005;39:199-202.
    • (2005) J Acquir Immune Defic Syndr , vol.39 , pp. 199-202
    • Pujari, S.N.1    Dravid, A.2    Naik, E.3
  • 21
    • 26844543445 scopus 로고    scopus 로고
    • Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides
    • Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818.
    • (2005) AIDS , vol.19 , pp. 1807-1818
    • Dube, M.P.1    Parker, R.A.2    Tebas, P.3
  • 22
    • 34247630552 scopus 로고    scopus 로고
    • Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens
    • Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007;45:34-42.
    • (2007) J Acquir Immune Defic Syndr , vol.45 , pp. 34-42
    • Anastos, K.1    Lu, D.2    Shi, Q.3
  • 23
    • 33746461336 scopus 로고    scopus 로고
    • Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
    • van Leth F, Hall DB, Lange JM, Reiss P. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med. 2006;7:347-350.
    • (2006) HIV Med , vol.7 , pp. 347-350
    • van Leth, F.1    Hall, D.B.2    Lange, J.M.3    Reiss, P.4
  • 24
    • 0006166138 scopus 로고    scopus 로고
    • Insulin resistance in HIV lipodystrophy syndrome
    • Hadigan C, Grinspoon S. Insulin resistance in HIV lipodystrophy syndrome. AIDS Clin Care. 2001; 13(2):1.
    • (2001) AIDS Clin Care , vol.13 , Issue.2 , pp. 1
    • Hadigan, C.1    Grinspoon, S.2
  • 25
    • 11344293751 scopus 로고    scopus 로고
    • Cardiovascular risk and body-fat abnormalities in HIV-infected adults
    • Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl j Med. 2005;352:48-62.
    • (2005) N Engl j Med , vol.352 , pp. 48-62
    • Grinspoon, S.1    Carr, A.2
  • 26
    • 30944431733 scopus 로고    scopus 로고
    • Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis
    • Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006; 185:1-11.
    • (2006) Atherosclerosis , vol.185 , pp. 1-11
    • Fisher, S.D.1    Miller, T.L.2    Lipshultz, S.E.3
  • 27
    • 33749168002 scopus 로고    scopus 로고
    • The changing face of HIV care: Common things really are common
    • Aberg JA. The changing face of HIV care: common things really are common. Ann Intern Med. 2006;145:463-465.
    • (2006) Ann Intern Med , vol.145 , pp. 463-465
    • Aberg, J.A.1
  • 28
    • 33746233466 scopus 로고    scopus 로고
    • Cardiovascular disease in HIV infection
    • Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J. 2006;151: 1147-1155.
    • (2006) Am Heart J , vol.151 , pp. 1147-1155
    • Sudano, I.1    Spieker, L.E.2    Noll, G.3
  • 29
    • 20944443940 scopus 로고    scopus 로고
    • Hospitalization for coronary heart disease and myocardial infarction among Northern California men with HIV-1 infection: Additional follow-up
    • February 8-11, San Francisco. Poster
    • Klein D, Hurley L, Quesenberry C, Sidney S. Hospitalization for coronary heart disease and myocardial infarction among Northern California men with HIV-1 infection: additional follow-up. 11th Conference on Retroviruses and Opportunistic Infections; February 8-11,2004; San Francisco. Poster 739.
    • (2004) 11th Conference on Retroviruses and Opportunistic Infections , pp. 739
    • Klein, D.1    Hurley, L.2    Quesenberry, C.3    Sidney, S.4
  • 30
    • 0345064200 scopus 로고    scopus 로고
    • Friis-Møller N, Sabin C, Weber R, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction [published correction appears in N Engl J Med. 2004;350:955]. N Engl J Med. 2003;349:1993-2003.
    • Friis-Møller N, Sabin C, Weber R, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction [published correction appears in N Engl J Med. 2004;350:955]. N Engl J Med. 2003;349:1993-2003.
  • 32
    • 33644895405 scopus 로고    scopus 로고
    • Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients
    • van Wijk JP, de Koning EJ, Cabezas MC, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol. 2006;47:1117-1123.
    • (2006) J Am Coll Cardiol , vol.47 , pp. 1117-1123
    • van Wijk, J.P.1    de Koning, E.J.2    Cabezas, M.C.3
  • 33
    • 33750730628 scopus 로고    scopus 로고
    • Endothelial dysfunction in HIV infection, 3:126-131
    • Cotter BR. Endothelial dysfunction in HIV infection. Curr HIV/AIDS Rep. 2006;3:126-131.
    • Curr HIV/AIDS Rep. 2006
    • Cotter, B.R.1
  • 34
    • 33748209571 scopus 로고    scopus 로고
    • Endothelial function in HIV-infected patients with low or mild cardiovascular risk
    • Blanco JJ, Garcia IS, Cerezo JG, et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother. 2006;58: 133-139.
    • (2006) J Antimicrob Chemother , vol.58 , pp. 133-139
    • Blanco, J.J.1    Garcia, I.S.2    Cerezo, J.G.3
  • 35
    • 33644919396 scopus 로고    scopus 로고
    • Cardiovascular risk in patients with human immunodeficiency virus infection: Incomplete data
    • Stein JH. Cardiovascular risk in patients with human immunodeficiency virus infection: incomplete data. J Am Coll Cardiol. 2006;47:1124-1125.
    • (2006) J Am Coll Cardiol , vol.47 , pp. 1124-1125
    • Stein, J.H.1
  • 36
    • 0037456351 scopus 로고    scopus 로고
    • Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection
    • Bozzette SA, Ake CF, Tarn HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
    • (2003) N Engl J Med , vol.348 , pp. 702-710
    • Bozzette, S.A.1    Ake, C.F.2    Tarn, H.K.3
  • 37
    • 0242267026 scopus 로고    scopus 로고
    • Klein D, Hurley LB, Sidney S. Cardiovascular disease and HIV infection. N Engl J Med. 2003;349:1869-1870; author reply 1869-1870.
    • Klein D, Hurley LB, Sidney S. Cardiovascular disease and HIV infection. N Engl J Med. 2003;349:1869-1870; author reply 1869-1870.
  • 38
    • 0037456433 scopus 로고    scopus 로고
    • Cardiovascular risk factors and antiretroviral therapy
    • Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. N Engl J Med. 2003; 348:679-680.
    • (2003) N Engl J Med , vol.348 , pp. 679-680
    • Kuritzkes, D.R.1    Currier, J.2
  • 39
    • 33748886125 scopus 로고    scopus 로고
    • Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use
    • Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS. 2006;20:1941-1950.
    • (2006) AIDS , vol.20 , pp. 1941-1950
    • Kwong, G.P.1    Ghani, A.C.2    Rode, R.A.3
  • 40
    • 0345357772 scopus 로고    scopus 로고
    • HIV infection and cardiovascular disease - is there really a link?
    • Sklar P, Masur H. HIV infection and cardiovascular disease - is there really a link? N Engl J Med. 2003;349:2065-2067.
    • (2003) N Engl J Med , vol.349 , pp. 2065-2067
    • Sklar, P.1    Masur, H.2
  • 41
    • 38349193415 scopus 로고    scopus 로고
    • Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis
    • In press
    • Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. In press.
    • Atherosclerosis
    • Lorenz, M.W.1    Stephan, C.2    Harmjanz, A.3
  • 42
    • 33751515147 scopus 로고    scopus 로고
    • + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
    • + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
  • 43
    • 0036596229 scopus 로고    scopus 로고
    • The significance of measuring non-HDL-cholesterol
    • Hirsch GA, Vaid N, Blumenthal RS. The significance of measuring non-HDL-cholesterol. Prev Cardiol. 2002;5:156-159.
    • (2002) Prev Cardiol , vol.5 , pp. 156-159
    • Hirsch, G.A.1    Vaid, N.2    Blumenthal, R.S.3
  • 44
    • 0002340211 scopus 로고    scopus 로고
    • Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: Summary of selected trials
    • Saag M, Powderly W, Schambelan M, et al. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Top HIV Med. 2002;10:47-51.
    • (2002) Top HIV Med , vol.10 , pp. 47-51
    • Saag, M.1    Powderly, W.2    Schambelan, M.3
  • 45
    • 64149111574 scopus 로고    scopus 로고
    • Parker R, Yang W, Wang S, et al. Transcriptional profiles support proteasome modulation hypothesis for lipid disturbances of current HIV-protease inhibitors and lipid neutrality of atazanavir. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; July 8-11, 2003; Paris. Antivir Ther. 2003;8(4):L49. Abstract 68.
    • Parker R, Yang W, Wang S, et al. Transcriptional profiles support proteasome modulation hypothesis for lipid disturbances of current HIV-protease inhibitors and lipid neutrality of atazanavir. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; July 8-11, 2003; Paris. Antivir Ther. 2003;8(4):L49. Abstract 68.
  • 46
    • 21844443541 scopus 로고    scopus 로고
    • Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
    • Keiser PH, Sension MG, DeJesus E, et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis. 2005;5:2.
    • (2005) BMC Infect Dis , vol.5 , pp. 2
    • Keiser, P.H.1    Sension, M.G.2    DeJesus, E.3
  • 47
    • 0032903844 scopus 로고    scopus 로고
    • Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
    • Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805-810.
    • (1999) AIDS , vol.13 , pp. 805-810
    • Martinez, E.1    Conget, I.2    Lozano, L.3
  • 48
    • 21844480420 scopus 로고    scopus 로고
    • Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia
    • Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051-1058.
    • (2005) AIDS , vol.19 , pp. 1051-1058
    • Calza, L.1    Manfredi, R.2    Colangeli, V.3
  • 49
    • 33746809138 scopus 로고    scopus 로고
    • Distribution, inter-conversion, and dose response of n-3 fatty acids in humans
    • Arterburn L, Hall E, Oken H. Distribution, inter-conversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006;83(suppl):1467S- 1476S.
    • (2006) Am J Clin Nutr , vol.83 , Issue.SUPPL.
    • Arterburn, L.1    Hall, E.2    Oken, H.3
  • 50
    • 0033954765 scopus 로고    scopus 로고
    • Polyunsaturaled fatty acids in the food chain in the United States
    • Kris-Etherton P, Taylor D, Yu-Poth S, et al. Polyunsaturaled fatty acids in the food chain in the United States. Am J Clin Nutr. 2000;71:179S-188S.
    • (2000) Am J Clin Nutr , vol.71
    • Kris-Etherton, P.1    Taylor, D.2    Yu-Poth, S.3
  • 51
    • 0030974010 scopus 로고    scopus 로고
    • n-3 Fatty acids and serum lipoproteins: Human studies
    • Harris WS. n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S-1654S.
    • (1997) Am J Clin Nutr , vol.65
    • Harris, W.S.1
  • 52
    • 0031425356 scopus 로고    scopus 로고
    • Safety and efficacy of Omacor in severe hypertriglyceridemia
    • Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385-391.
    • (1997) J Cardiovasc Risk , vol.4 , pp. 385-391
    • Harris, W.S.1    Ginsberg, H.N.2    Arunakul, N.3
  • 53
    • 1642528026 scopus 로고    scopus 로고
    • Fish oil supplementation: Evidence for health benefits
    • Harris WS. Fish oil supplementation: evidence for health benefits. Cleve Clin J Med. 2004;71:208-221.
    • (2004) Cleve Clin J Med , vol.71 , pp. 208-221
    • Harris, W.S.1
  • 54
    • 33746824712 scopus 로고    scopus 로고
    • n-3 Fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits
    • Gebauer SK, Psota TL, Harris WS, Kris-Etherton PM. n-3 Fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. Am J Clin Nutr. 2006;83(6 suppl): 1526S-1535S.
    • (2006) Am J Clin Nutr , vol.83 , Issue.6 SUPPL.
    • Gebauer, S.K.1    Psota, T.L.2    Harris, W.S.3    Kris-Etherton, P.M.4
  • 55
    • 0037137299 scopus 로고    scopus 로고
    • American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
    • Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-2757.
    • (2002) Circulation , vol.106 , pp. 2747-2757
    • Kris-Etherton, P.M.1    Harris, W.S.2    Appel, L.J.3
  • 56
    • 3042596046 scopus 로고    scopus 로고
    • Fish and shellfish as dietary sources of methylmercury and the omega-3 fatty acids, eicosahexaenoic acid and docosahexaenoic acid: Risks and benefits
    • Mahaffey KR. Fish and shellfish as dietary sources of methylmercury and the omega-3 fatty acids, eicosahexaenoic acid and docosahexaenoic acid: risks and benefits. Environ Res. 2004;95:414-428.
    • (2004) Environ Res , vol.95 , pp. 414-428
    • Mahaffey, K.R.1
  • 57
    • 64149100653 scopus 로고    scopus 로고
    • Omacor (omega-3 fatty acid ethyl esters) [prescribing information]. Liberty Corner, NJ: Reliant Pharmaceuticals, Inc; September 2005. Available at: http://www.omacorrx.com/OMACOR/OMACOR-Prescribing-Information.pdf. Accessed May 29, 2007.
    • Omacor (omega-3 fatty acid ethyl esters) [prescribing information]. Liberty Corner, NJ: Reliant Pharmaceuticals, Inc; September 2005. Available at: http://www.omacorrx.com/OMACOR/OMACOR-Prescribing-Information.pdf. Accessed May 29, 2007.
  • 59
    • 0038281520 scopus 로고    scopus 로고
    • Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
    • Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455-463.
    • (2003) J Lipid Res , vol.44 , pp. 455-463
    • Park, Y.1    Harris, W.S.2
  • 60
    • 0036325388 scopus 로고    scopus 로고
    • Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia
    • Chan D, Watts G, Beilin L, et al. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002;51: 2377-2386.
    • (2002) Diabetes , vol.51 , pp. 2377-2386
    • Chan, D.1    Watts, G.2    Beilin, L.3
  • 61
    • 0036124659 scopus 로고    scopus 로고
    • N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials
    • Bucher H, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298-304.
    • (2002) Am J Med , vol.112 , pp. 298-304
    • Bucher, H.1    Hengstler, P.2    Schindler, C.3    Meier, G.4
  • 62
    • 2342518735 scopus 로고    scopus 로고
    • Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ). Mar 2004:(93):l-6.
    • Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ). Mar 2004:(93):l-6.
  • 63
    • 0024334111 scopus 로고
    • Fish oils and plasma lipid and lipoprotein metabolism in humans: A critical review
    • 63
    • 63.Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989;30:785-807.
    • (1989) J Lipid Res , vol.30 , pp. 785-807
    • Harris, W.S.1
  • 64
    • 0019253557 scopus 로고
    • The effects of salmon oil upon plasma lipids, lipoproteins, and triglyceride clearance
    • Harris WS, Connor WE. The effects of salmon oil upon plasma lipids, lipoproteins, and triglyceride clearance. Trans Assoc Am Physicians. 1980;93:148-155.
    • (1980) Trans Assoc Am Physicians , vol.93 , pp. 148-155
    • Harris, W.S.1    Connor, W.E.2
  • 65
    • 0025948301 scopus 로고
    • n-3 Fatty acid supplements reduce chylomicron levels in healthy volunteers
    • Harris W, Windsor S. n-3 Fatty acid supplements reduce chylomicron levels in healthy volunteers. J Atheroscler Tliromb. 1991;43:5-15.
    • (1991) J Atheroscler Tliromb , vol.43 , pp. 5-15
    • Harris, W.1    Windsor, S.2
  • 66
    • 0024244314 scopus 로고
    • Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids
    • Harris WS, Connor WE, Alam N, Illingworth DR. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res. 1988;29:1451-1460.
    • (1988) J Lipid Res , vol.29 , pp. 1451-1460
    • Harris, W.S.1    Connor, W.E.2    Alam, N.3    Illingworth, D.R.4
  • 67
    • 0024246814 scopus 로고
    • Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism
    • Weintraub MS, Zechner R, Brown A, et al. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest. 1988;82:1884-1893.
    • (1988) J Clin Invest , vol.82 , pp. 1884-1893
    • Weintraub, M.S.1    Zechner, R.2    Brown, A.3
  • 68
    • 0027104290 scopus 로고
    • Effects of n-3 fatty acids on postprandial triacylglycerol and hormone concentrations in normal subjects
    • Williams CM, Moore F, Morgan L, Wright J. Effects of n-3 fatty acids on postprandial triacylglycerol and hormone concentrations in normal subjects. Br J Nutr. 1992;68:655-666.
    • (1992) Br J Nutr , vol.68 , pp. 655-666
    • Williams, C.M.1    Moore, F.2    Morgan, L.3    Wright, J.4
  • 69
    • 7944220192 scopus 로고    scopus 로고
    • Treatment of hypertriglyceridemia with omega-3 fatty acids: A systematic review
    • Lewis A, Lookinland S, Beckstrand R, Tiedeman M. Treatment of hypertriglyceridemia with omega-3 fatty acids: a systematic review. J Am Acad Nurse Pract. 2004;16:384-395.
    • (2004) J Am Acad Nurse Pract , vol.16 , pp. 384-395
    • Lewis, A.1    Lookinland, S.2    Beckstrand, R.3    Tiedeman, M.4
  • 70
    • 0034762548 scopus 로고    scopus 로고
    • An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
    • Durrington P, Bhatnagar D, Mackness M, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:544-548.
    • (2001) Heart , vol.85 , pp. 544-548
    • Durrington, P.1    Bhatnagar, D.2    Mackness, M.3
  • 71
    • 0037307248 scopus 로고    scopus 로고
    • Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity
    • Chan D, Watts G, Mori T, et al. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr. 2003;77:300-307.
    • (2003) Am J Clin Nutr , vol.77 , pp. 300-307
    • Chan, D.1    Watts, G.2    Mori, T.3
  • 72
    • 0033963643 scopus 로고    scopus 로고
    • Omacor in familial combined hyperlipidemia: Effects on lipids and low density lipoprotein subclasses
    • Calabresi L, Donati D, Pazzucconi F, et al. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000;148:387-396.
    • (2000) Atherosclerosis , vol.148 , pp. 387-396
    • Calabresi, L.1    Donati, D.2    Pazzucconi, F.3
  • 73
    • 0032917836 scopus 로고    scopus 로고
    • Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins
    • Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285-297.
    • (1999) Atherosclerosis , vol.143 , pp. 285-297
    • Pownall, H.J.1    Brauchi, D.2    Kilinc, C.3
  • 74
    • 0031800499 scopus 로고    scopus 로고
    • The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia
    • Borthwick L. The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin Drug Invest. 1998;15:397-404.
    • (1998) Clin Drug Invest , vol.15 , pp. 397-404
    • Borthwick, L.1
  • 75
    • 0028555395 scopus 로고
    • Effects of new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia
    • Mackness M, Bhatnagar D, Durrington P, et al. Effects of new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr. 1994;48:859-865.
    • (1994) Eur J Clin Nutr , vol.48 , pp. 859-865
    • Mackness, M.1    Bhatnagar, D.2    Durrington, P.3
  • 76
    • 0028960421 scopus 로고
    • Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia
    • Grundt H, Nilsen DW, Hetland O, et al. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. J Intern Med. 1995;237:249-259.
    • (1995) J Intern Med , vol.237 , pp. 249-259
    • Grundt, H.1    Nilsen, D.W.2    Hetland, O.3
  • 77
    • 33947113384 scopus 로고    scopus 로고
    • Safety considerations with omega-3 fatty acid therapy
    • Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99:35C-43C.
    • (2007) Am J Cardiol , vol.99
    • Bays, H.E.1
  • 78
    • 4444299083 scopus 로고    scopus 로고
    • Variable hypocoagulant effect of fish oil intake in humans: Modulation of fibrinogen level and thrombin generation (includes materials and methods addendum)
    • Vanschoonbeek K, Feijge M, Paquay M, et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation (includes materials and methods addendum). Arterioscler Thromb Vase Biol. 2004;24:1734-1740.
    • (2004) Arterioscler Thromb Vase Biol , vol.24 , pp. 1734-1740
    • Vanschoonbeek, K.1    Feijge, M.2    Paquay, M.3
  • 79
    • 0031746608 scopus 로고    scopus 로고
    • Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy
    • Bender N, Kraynak M, Chiquette E, et al. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis. 1998;5:257-261.
    • (1998) J Thromb Thrombolysis , vol.5 , pp. 257-261
    • Bender, N.1    Kraynak, M.2    Chiquette, E.3
  • 80
    • 33745063941 scopus 로고    scopus 로고
    • Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters
    • 80
    • 80.McKenney JM, Swearingen D, Di Spirito M, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol. 2006;46:785-791.
    • (2006) J Clin Pharmacol , vol.46 , pp. 785-791
    • McKenney, J.M.1    Swearingen, D.2    Di Spirito, M.3
  • 81
    • 0037040378 scopus 로고    scopus 로고
    • Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
    • Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577.
    • (2002) AIDS , vol.16 , pp. 569-577
    • Fichtenbaum, C.J.1    Gerber, J.G.2    Rosenkranz, S.L.3
  • 82
    • 64149110156 scopus 로고    scopus 로고
    • Polyunsaturated ethyl esters of n-3 fatty acids in HTV-infected patients with moderate hypertriglyceridemia: Comparison with dietary and lifestyle changes, and fibrate therapy
    • Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters of n-3 fatty acids in HTV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Cardiovasc Risk. 2004;36:876-881.
    • (2004) J Cardiovasc Risk , vol.36 , pp. 876-881
    • Manfredi, R.1    Calza, L.2    Chiodo, F.3
  • 83
    • 0035199219 scopus 로고    scopus 로고
    • Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: A randomized prospective trial
    • de Luis Roman DA, Bachiller P, Izaola O, et al. Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: a randomized prospective trial. Eur J Clin Nutr. 2001;55:1048-1052.
    • (2001) Eur J Clin Nutr , vol.55 , pp. 1048-1052
    • de Luis Roman, D.A.1    Bachiller, P.2    Izaola, O.3
  • 84
    • 33750854699 scopus 로고    scopus 로고
    • The safety and efficacy of fish oil in combination with fenofibrate in subjects on ART with hypertriglyceridemia who had an incomplete response to either agent alone: Results of ACTG A5186
    • February 5-8, Denver. Abstract 146
    • Gerber J, Kitch D, Aberg J, et al. The safety and efficacy of fish oil in combination with fenofibrate in subjects on ART with hypertriglyceridemia who had an incomplete response to either agent alone: results of ACTG A5186. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver. Abstract 146.
    • (2006) 13th Conference on Retroviruses and Opportunistic Infections
    • Gerber, J.1    Kitch, D.2    Aberg, J.3
  • 85
    • 33749175714 scopus 로고    scopus 로고
    • Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City
    • Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406.
    • (2006) Ann Intern Med , vol.145 , pp. 397-406
    • Sackoff, J.E.1    Hanna, D.B.2    Pfeiffer, M.R.3    Torian, L.V.4
  • 86
    • 33751568894 scopus 로고    scopus 로고
    • Risk of cardiovascular disease in a cohort of HIV-infected adults: A study using carotid intima-media thickness and coronary artery calcium score
    • Mangili A, Gerrior J, Tang AM, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis. 2006;43:1482-1489.
    • (2006) Clin Infect Dis , vol.43 , pp. 1482-1489
    • Mangili, A.1    Gerrior, J.2    Tang, A.M.3
  • 87
    • 33747122345 scopus 로고    scopus 로고
    • Metabolic and skeletal complications of HIV infection: The price of success
    • Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA. 2006;296:844-854.
    • (2006) JAMA , vol.296 , pp. 844-854
    • Morse, C.G.1    Kovacs, J.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.